Supplementary Methods, Figures 1-9, Table 1 from rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Authors:
- Xiaowen GeXGXiaowen Ge
- Lin WuLWLin Wu
- Weiguo HuWHWeiguo Hu
- Stacey FernandesSFStacey Fernandes
- Chun WangCWChun Wang
- Xu LiXLXu Li
- Jennifer R. BrownJBJennifer R. Brown
- Xuebin QinXQXuebin Qin
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)